Choroideremia Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Choroideremia Pipeline Analysis report covers 5 drugs currently in different phases of development. Choroideremia is a rare inherited disorder characterised by progressive vision loss due to degeneration of the choriocapillaris, retinal pigment epithelium, and the photoreceptor of the eye. Symptoms of the disease are night-blindness, vision loss in mid periphery and appearance of the blind spots and may lead to complete blindness. It is genetic defect of X-chromosome thus mostly affect the males.
The report provides Choroideremia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are 4D Molecular Therapeutics, Horama S.A., Nightstar Therapeutics, RegenXbio and Spark Therapeutics.
By Molecule Type
By Route of Administration